Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Docetaxel monotherapy.
Triple Negative Breast Cancer
DRUG: BLEX 404 Oral Liquid
Phase I: Dose-limiting toxicity (DLT) observation, Presence or absence of dose-limiting toxicity (DLT) related to BLEX 404 Oral Liquid for each patient during first cycle of Docetaxel monotherapy to determine the recommended dose level (RDL)., 3 weeks (1 cycle)|Phase II: Overall response rate (PR + CR), Overall response rate (PR + CR) after 4 cycles of combination use in BLEX 404 + Docetaxel monotherapy., 12 weeks (4 cycles)
Phase II: Overall response rate (PR + CR)(at least 1 cycle), Overall response rate (PR + CR) after at least 1 cycle of combination use in BLEX 404 + Docetaxel monotherapy., at least 3 weeks (1 cycle)|Phase II: Incidence of grade 3/4 hematological toxicity, Rate of grade 3/4 hematological toxicity of each cycle., 3 weeks (1 cycle)|Quality of Life by EORTC QLQ-C30, Examination of quality of life by EORTC QLQ-C30 questionnaire of each cycle., 3 weeks (1 cycle)
The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Docetaxel monotherapy.